All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Athena Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2021
Details:
The licensed product upon launch, will be the only once-daily formulation containing an established Active Pharmaceutical Ingredient (API), which physicians can optionally prescribe alone or concomitantly with other antihypertensive agents to pursue desired outcomes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paclitaxel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SurVeil DCB
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
TRANSCEND revealed that achieving clinically safe and effective outcomes with a substantially lower dose of Paclitaxel is achievable with the SurVeil DCB. SurVeil, is coated with a significantly lower dose of the drug paclitaxel than Medtronic's IN.PACT balloon.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Medicure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
Details:
The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Coenzyme Q10
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ubiquinol
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day; Ubiquinol 100 mg/day; placebo).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Everolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESPRIT BTK
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
